Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.


a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production (erythropoiesis).
recombinant human erythropoietin epoetin.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

e·ryth·ro·poi·e·tin (EPO),

(ĕ-rith'rō-poy'ĕ-tin), [MIM*133170]
A protein containing sialic acid that enhances erythropoiesis by stimulating formation of proerythroblasts and release of reticulocytes from bone marrow; it is formed by the kidney and liver, and possibly by other tissues, and can be detected in human plasma and urine.
Farlex Partner Medical Dictionary © Farlex 2012


1. A glycoprotein hormone that stimulates the production of red blood cells by stem cells in bone marrow. Produced mainly by the kidneys, it is released in response to decreased levels of oxygen in body tissue.
2. Epoetin alfa.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


A gene on chromosome 7q22 that encodes erythropoietin, a secreted, glycosylated cytokine found in the plasma, which regulates red cell production by promoting erythroid differentiation and initiating haemoglobin synthesis. Erythropoietin plays a neuroprotective role in response to brain injury and is antiapoptotic.

Molecular pathology
Genetic variability of EPO has been linked to microvascular complications of diabetes type 2, including diabetic retinopathy, nephropathy leading to end-stage renal disease, and neuropathy
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.


EPO Physiology A 46 kD glycoprotein colony-stimulating factor produced predominantly by cells adjacent to the proximal renal tubules in response to signals from an oxygen-sensitive substances in the kidneys–eg, heme Adverse effects Chest pain, swelling, tachycardia, headache, HTN; erythropoietin–EP binds to receptors in erythroid precursors that mature into RBCs; EP is ↑ by hypoxia or by ectopic production from tumors–eg, cerebellar hemangioblastoma, hepatoma, pheochromocytoma, uterine leiomyoma, and renal cell carcinoma; it may not be ↑ in anemic premature infants, and is ↓ in 2º anemia, chronic inflammation, P vera, and certain CAs and may be useful in myeloma-related anemia; EP therapy is indicated for HIV-related anemia, anemia of renal failure and prematurity; it ↑ number of units of autologous RBCs that may be donated before surgery, for ↑ number of units that may be phlebotomized in Pts with hemochromatosis and to ↑ units that may be drawn from a person with a rare blood type
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.


A protein that enhances erythropoiesis by stimulating formation of proerythroblasts and releasing reticulocytes from bone marrow; secreted mainly by the kidney and possibly by other tissues.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012


A hormone produced by the kidneys that stimulates the production of red blood cells by bone marrow.
Mentioned in: Dialysis, Kidney
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
Erythropoietin Drugs Market Revenue, by Geography (US$ Mn), 2015-2025
Protective effect of erythropoietin against 1-methyl-4-phenylpyridinium-induced neurodegenaration in PC12 cells.
Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature.
There was a significant difference between erythropoietin levels at admission, after 48 and 72 hours, and on day 7 of hospital stay.
One of JAK2V617F negative male patient who presented in surgical department for operating inguinal hernia, incidentally diagnosed as having polycythemia and had low serum erythropoietin levels.
The US is one of the key revenue contributors to the erythropoietin drugs market in the Americas, where there are ample opportunities for the expansion of the market.
Erythropoietin Improves Oligodendrocyte Survival after Hyperoxia but Does Not Influence Hypomyelination and Long-Term Structural White Matter Injury.
The major exclusion criteria were: pregnancy (diagnosed by detection of human chorionic gonadotropine levels), patients with hypersensitivity to erythropoietin [beta], administration of other ESA, hemoglobin (Hb) levels above 10.5 g/dl, unregulated hyperparathyroidism (intact parathormone (iPTH) >300 pg/ml), hypertension not regulated with the administered therapy ([greater than or equal to]160/100 mmHg), history of myocardial infarction, unstable angina, thromboembolic disease and cerebrovascular insult during the last six months.
EPO's alter ego: erythropoietin has multiple actions.
Another new erythropoietin derivative with successfully prolonged half-life has been reported recently [10].

Full browser ?